Laboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Department of Genetics, Wroclaw Medical University, Wrocław, Poland.
Front Cell Infect Microbiol. 2021 Feb 26;11:630052. doi: 10.3389/fcimb.2021.630052. eCollection 2021.
Research on the use of fecal microbiota transplantation (FMT) in the treatment of disorders related to digestive system ailments in children with autism spectrum disorders (ASDs) is a new attempt in a therapeutic approach. There are very little scientific evidences available on this emerging alternative method. However, it appears to be interesting not only because of its primary outcome, relieving the gastrointestinal (GI) symptoms, but also secondary therapeutic effect of alleviating autistic behavioral symptoms. FMT seems to be also promising method in the treatment of another group of pediatric patients, children with inflammatory bowel disease (IBD). The aim of this study is to discuss the potential use of FMT and modified protocols (MTT, microbiota transfer therapy) in the treatment of GI disorders in ASD children supported by reports on another disease, IBD concerning pediatric patients. Due to the few reports of the use of FMT in the treatment of children, these two patients groups were selected, although suffering from distant health conditions: neurodevelopmental disorder and gastrointestinal tract diseases, because of the the fact that they seem related in aspects of the presence of GI symptoms, disturbed intestinal microbiota, unexplained etiology of the condition and age range of patients. Although the outcomes for all are promising, this type of therapy is still an under-researched topic, studies in the group of pediatric patients are sparse, also there is a high risk of transmission of infectious and noninfectious elements during the procedure and no long-term effects on global health are known. For those reasons all obtained results should be taken with a great caution. However, in the context of future therapeutic directions for GI observed in neurodevelopmental disorders and neurodegenerative diseases, the topic seems worthy of attention.
关于自闭症谱系障碍（ASD）儿童中与消化系统疾病相关的紊乱使用粪便微生物群移植（FMT）治疗的研究是一种治疗方法的新尝试。这种新兴替代方法的科学证据非常少。然而，它不仅因其主要结果缓解胃肠道（GI）症状，而且还因其缓解自闭症行为症状的次要治疗效果而显得有趣。FMT 似乎也是另一组儿科患者，即炎症性肠病（IBD）儿童的有前途的治疗方法。本研究旨在讨论 FMT 和改良方案（MTT，微生物转移治疗）在 ASD 儿童 GI 疾病治疗中的潜在用途，该方案基于涉及儿科患者的另一疾病 IBD 的报告。由于 FMT 在儿童治疗中的应用报告很少，因此选择了这两个患者群体，尽管他们患有距离较远的健康状况：神经发育障碍和胃肠道疾病，因为他们在存在 GI 症状，肠道微生物群紊乱，疾病病因不明和患者年龄范围方面似乎存在关联。尽管所有结果都很有希望，但这种治疗类型仍然是一个研究不足的课题，儿科患者群体的研究稀疏，并且在该过程中存在传染性和非传染性元素传播的高风险，并且对全球健康的长期影响尚不清楚。出于这些原因，所有获得的结果都应谨慎对待。然而，在神经发育障碍和神经退行性疾病中观察到的 GI 的未来治疗方向的背景下，该主题似乎值得关注。
